Photo - EM-CATH by SremCath
play_arrow
View
56458

EM-CATH by SremCath

Serbia
Market: Medicine
Stage of the project: Idea or something is already done

Date of last change: 08.03.2022
Show contacts
4
equalizer from 2000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:
 

Idea

EM-CATH is a next level urinary catheter which does not insert bacteria into the sterile parts of urinary tract, intended both for intermittent and indwelling use, and significantly cuts costs

Current Status

EM-CATH received the Written Opinion of the International Searching Authority confirming the novelty, inventive steps and industrial applicability for all 12 claims. Currently EM-CTH is in national phase of the Patent Cooperation Treaty (PCT) procedure in USA, Europe, Canada, Israel, Russia and China. SremCath company was established in June 2019 and exclusive unconditional license was granted for EM-CATH . A 3-D printed prototype was made. The next step will be small scale production of a sterile finished product ready for pre-clinical and clinical trials.

Problem or Opportunity

Catheter-associated urinary tract infections are killing more people than all traffic accidents worldwide! They also generate further medical conditions, as well as economical, financial, psycho-social burden

Solution (product or service)

We have solution to this problem – EM CATH – innovative urinary catheter, which prevents introducing bacteria into the urinary tract, most of which are multi-resistant. EM-CATH aims to reduce complications related to use of urinary catheters by 50%, to save lives and significantly improve quality of life of millions of patients worldwide, to substantially increase the quality of medical treatment, and to reduce costs of treatment of all medical conditions requiring urinary catheterization.

Business model

EM-CATH provides urinary catheterization without infection, with less complications, discomfort, pain and suffering, restores overall functionality and significantly cuts catheterization-related costs.
EM-CATH’s main market is B2B: predominantly health insurance funds (HIFs), also healthcare institutions (HCs), home and community care (assisted living, rehabilitation).
Main users are elderly – rapidly growing segment.
Most important activities include development, regulatory, marketing and sales.
Main sales channel is direct sales to HIFs and HCs and indirect sales through distributors.

Incubation/Acceleration programs accomplishment

EM-CATH participated at ImagineIF accelerator programme.

SremCath also participated in ImpactHub Serbia accelerator general training programme.

EM-CATH won national contest and second place on the global ImagineIF contest in Cambridge, June 2019
5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility174
star0
Add to favorites
Delete from favorites
share
close
thumb_up1
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Photos
Product Video